Name: Magaldrate

---

Type: small molecule

---

Groups: withdrawn

---

Indication: Not Available

---

Accession Number: DB08938 ( DB08938)

---

Description: Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

---

Structure:

---

Prescription Products: Not Available

---

Generic Prescription Products: Not Available

---

Over the Counter Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Riopan Chewable Tablets 480mg	tablet	480 mg	oral	31-12-1994	31-07-2002	Canada
Riopan Sus 480mg/5ml	suspension	480 mg	oral	31-12-1993	19-07-2002	Canada
Riopan Suspension 480mg/5ml	suspension	480 mg	oral	31-12-1994	31-07-2002	Canada
Riopan Tab 480mg	tablet	480 mg	oral	31-12-1993	19-07-2002	Canada

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients
Riopan Sus 480mg/5ml	Magaldrate
Riopan Tab 480mg	Magaldrate
Riopan Suspension 480mg/5ml	Magaldrate
Riopan Chewable Tablets 480mg	Magaldrate

Brand Name	Ingredients
Riopan Sus 480mg/5ml	Magaldrate
Riopan Tab 480mg	Magaldrate
Riopan Suspension 480mg/5ml	Magaldrate
Riopan Chewable Tablets 480mg	Magaldrate

---

Categories

• No Category

Indication: Not Available

---

Pharmacodynamics: Not Available

---

Mechanism of action: Not Available

---

Absorption: Not Available

---

Volume of distribution: Not Available

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces. Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces.

---

Half life: Not Available

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Not Available

---

Dosage forms

Form	Route	Strength
Suspension	oral	480 mg
Tablet	oral	480 mg

Form	Route	Strength
Suspension	oral	480 mg
Tablet	oral	480 mg

---

Prices

Unit description	Cost	Unit

Unit description	Cost	Unit

---

Patents

Country	Patent Number	Approved	Expires (estimated)

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Not Available

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Not Available

---

substituent:

• Not Available

Synthesis Reference: U.S. Patent 2,923,660.

---

General Reference: # Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8462913 # Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1790087

---

External Links:

Resource	Link
Drugs.com	http://www.drugs.com/international/magaldrate.html

Resource	Link
Drugs.com	http://www.drugs.com/international/magaldrate.html

---

ATC Codes:

• Array

---

AHFS Codes:

• Not Available

---

MSDS: Download